18th week of 2022 patent applcation highlights part 11 |
Patent application number | Title | Published |
20220133721 | METHOD FOR TREATING CANCER - The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to methods for treatment of these types of cancer. In particular, the disclosure relates to the combined use of of an inhibitor of a protein of the MAPK/ERK pathway and an inhibitor of specific kinases in the treatment of a cancer, in particular melanoma, in a patient. In an important embodiment, the cancer is characterized by the absence or reduced expression of MITF. | 2022-05-05 |
20220133722 | PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical compositions for the treatment or prevention of symptoms associated with endocrine disturbances, such as hot flashes. The pharmaceutical compositions comprise a tricyclic amino containing compound of formula (I), such as MSX-122 (also known as “Q-122”) (N,N′-(1,4-phenylenebis(methylene))bis(pyrimidin-2-amine)), and one or more pharmaceutically acceptable excipients. The pharmaceutical compositions may be given in certain doses and/or dosing regimens, preferably twice daily. | 2022-05-05 |
20220133723 | (4-((3R,4R)-3-METHOXYTETRAHYDRO-PYRAN-4-YLAMINO)PIPERIDIN-1-YL)(5-METHYL-6- -(((2R,6S)-6-(P-TOLYL)TETRAHYDRO-2H-PYRAN-2-YL)METHYLAMINO)PYRIMIDIN-4-YL)- METHANONE CITRATE - The invention provides a salt of a tetrahydropyranylmethylaminopyrimidine amide, such as the citrate salt of (4-((3R,4R)-3-methoxytetrahydropyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone, pharmaceutical compositions containing the same, processes for preparing the same, and methods of medical treatment using the same. | 2022-05-05 |
20220133724 | METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS - The present disclosure provides methods of mitigating thiamine deficiency. | 2022-05-05 |
20220133725 | PULSE DOSING REGIMEN AND METHODS OF TREATMENT - A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein. | 2022-05-05 |
20220133726 | TRIAMTERENE OR NOLATREXED FOR USE IN THE TREATMENT OF PHENYLKETONURIA - The present invention relates to a compound selected from the group consisting of nolatrexed, triamterene, sultopride and hydrastinine or a pharmaceutically acceptable salt thereof, preferably triamterene, nolatrexed or a pharmaceutically acceptable salt thereof, and to combination of said compounds with other active ingredients, for use in the treatment and/or prevention of phenylketonuria, to the use of said compound or its combinations in the manufacture of a medicament for the treatment or prevention of said diseases and to a method of treating and/or preventing by administration of said compound or its combinations. | 2022-05-05 |
20220133727 | COMBINATION THERAPIES FOR USE IN TREATING CANCER - The compound of Formula (I), or pharmaceutically acceptable salts thereof, is useful in, among other things, the treatment of MTAP-deficient lung cancer, such as NSCLC, or MTAP-deficient pancreatic cancer, such as PDAC, or MTAP-deficient esophageal cancer and provides a therapeutic advantage when used in combination with other agents as herein described compared to treatment with each agent when administered alone. | 2022-05-05 |
20220133728 | METHODS FOR TREATING VITILIGO LESIONS HAVING IMPROVED EFFICACY - Methods for treating vitiligo lesions including administering to a patient having vitiligo lesions a combination of a topical treatment and ultraviolet B (“UVB”) phototherapy. As disclosed herein, the inventors of the present invention have made the surprising discovery that the JAK inhibitor SHR0302 applied topically combined with narrowband UVB phototherapy dramatically repigments vitiligo lesions, including vitiligo lesions of the face and neck. | 2022-05-05 |
20220133729 | COMPOSITIONS AND METHODS FOR TREATING BASAL FOREBRAIN DISEASE - The present invention provides methods and compositions for treatment of Dementia with Lewy Bodies. | 2022-05-05 |
20220133730 | Compositions and Methods for the Prevention and Treatment of Hearing Loss - Method, kit and pharmaceutical compositions using an inhibitor of EGFR signaling for prevention or treatment of hearing loss are described. | 2022-05-05 |
20220133731 | ACYL-COA SYNTHETASE 4 (ACSL4) INHIBITORY COMPOUND - A new compound of formula A for the treatment of aggressive and/or resistant tumors expressing acyl-CoA synthetase 4 (ACSL4) and/or depending on steroids action. More particularly, the compound of the present invention inhibits tumor growth in ACSL4-expressing breast and prostate cancers, inhibits steroid synthesis and sensitizes cells towards chemotherapeutic and hormone therapy agents. Pharmaceutical compositions comprising the ACSL4-inhibitory compound of the invention, pharmaceutical combinations thereof with other anticancer agents and use in therapy. | 2022-05-05 |
20220133732 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CAIX - The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of carbonic anhydrase IX (CAIX).The invention also includes dmg conjugates comprising said peptides,conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CAIX. | 2022-05-05 |
20220133733 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD38 - The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD38. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD38. | 2022-05-05 |
20220133734 | SUBSTITUTED 1H-PYRAZOLO[4,3-C]PYRIDINES AND DERIVATIVES AS EGFR INHIBITORS - The present invention encompasses compounds of formula (I) | 2022-05-05 |
20220133735 | CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOF - Described herein are crystalline forms of compounds that are deoxycytidine kinase (dCK) inhibitors, methods of making such crystalline forms, pharmaceutical compositions and medicaments comprising such crystalline forms, and methods of using such crystalline forms in the treatment of conditions, diseases, or disorders that would benefit from modulation of deoxycytidine kinase (dCK) activity. | 2022-05-05 |
20220133736 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS - The present disclosure provides methods of increasing skin pigmentation in a subject in need thereof using salt-inducible kinase (SIK) inhibitors, such as macrocyclic compounds of Formula (I), bicyclic urea compounds of Formula (II), (III), and (IV), and compounds of Formula (V), (VI), (VI-A), or (VII). Also provided are pharmaceutical compositions, methods, and uses that include or involve a compound described herein. | 2022-05-05 |
20220133737 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS - The present disclosure relates to methods for treating bronchiectasis, for example, non-cystic fibrosis bronchiectasis with compositions comprising an effective amount of certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds of Formula (I), including pharmaceutically acceptable salts thereof, | 2022-05-05 |
20220133738 | GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY - Provided herein are methods for treating or ameliorating cholestatic liver disease in a subject in need thereof. The methods include administering an Apical Sodium-dependent Bile Acid Transport Inhibitor (ASBTI) to the subject. The methods include determining a genotype of the subject and predicting subject response to the ASBTI administration based upon the genotype. The methods further include determining, adjusting, or modulating a dose of the ASBTI administered to the subject based upon the genotype or upon measurements of clinically relevant disease parameters. | 2022-05-05 |
20220133739 | METHODS AND FORMULATIONS FOR TREATMENT OF AND/OR PROTECTION AGAINST ACUTE LIVER FAILURE AND OTHER HEPATOTOXIC CONDITIONS - Methods for treating and/or protecting against acute liver failure and other hepatotoxicities in an individual employ a combination of a first active agent comprising N-acetylcysteine and a second active agent comprising a manganese complex selected from the group consisting of (i) a calcium manganese mixed metal complex of N,N′-bis-(pyridoxal-5-phosphate)-ethylenediamine-N,N′-diacetic acid (DPDP) having a molar ratio of calcium to manganese in a range of from 1 to 10, or a pharmaceutically acceptable salt thereof, (ii) a mixture of manganese DPDP (MnDPDP), or a pharmaceutically acceptable salt thereof, and a non-manganese-containing DPDP compound, or (iii) a mixture of manganese pyridoxyl ethylenediamine (MnPLED), or a pharmaceutically acceptable salt thereof, and a non-manganese-containing pyridoxyl ethylenediamine (PLED) compound. | 2022-05-05 |
20220133740 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS - The present invention provides methods for treating diseases and disorders of the ear with valproic acid compounds and Wnt agonists. The present invention further provides kits for the same. | 2022-05-05 |
20220133741 | AAntihistamines In Combination With A Range Of Substances For Improved Health - The present invention provides for novel combinations comprising an antihistamine with selected pharmaceutical and nutraceutical agents which alleviate some of the symptoms experienced by menopausal women, optionally combined further with a range of indole-based natural products such as L-tryptophan, 5-hydroxytryptophan and melatonin. These mixtures may be enriched further with pharmaceutically acceptable calcium and magnesium salts as well as selected B vitamins. These combinations have utility in providing a medicament for improving health in mammals, especially for the improvement of menopausal symptoms as well as sleep in women. | 2022-05-05 |
20220133742 | METHODS OF TREATING CONGENITAL ADRENAL HYPERPLASIA - Patients with congenital adrenal hyperplasia (CAH) need adequate care and treatment in order to lead normal lives. Hence, there is a need for new methods of treating CAH. This disclosure provides new compounds, salts, compositions and uses thereof in the treatment of CAH. | 2022-05-05 |
20220133743 | TOPICAL TREATMENT OF WOUNDS WITH STATINS AND CHOLESTEROL FOR SCAR REDUCTION - Provided herein are compositions, systems, and methods for treating wounds with the combination of statins and cholesterol to help prevent and reduce scar formation. | 2022-05-05 |
20220133744 | COMPOSITION OF LANOSTEROL PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF - Disclosed are a composition comprising a compound as shown in formula (I) and a preparation method therefor, and the use of same in the preparation of a drug for treating ophthalmic diseases. | 2022-05-05 |
20220133745 | COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE - The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions. | 2022-05-05 |
20220133746 | METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISTS AND BREAST CANCER - Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound. | 2022-05-05 |
20220133747 | ESTROGEN RECEPTOR INHIBITORS AND USES THEROF - Described herein, inter alia, are compositions and methods for treating or preventing hyperproliferative disorders, including cancer. | 2022-05-05 |
20220133748 | METHODS AND COMPOSITIONS FOR INHIBITING THE NLRP3 INFLAMMASOME AND/OR LON PROTEASE - The present invention relates to methods, compositions, and combinations for inhibiting the NLRP3 inflammasome and/or LON protease as well as methods, compositions, and combinations for treating cancer, particularly blood cancer or brain cancer. In certain aspects, the compositions and combinations include a synthetic triterpenoid, such as 1-[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4(-pyridin-2-yl)-1H-imidazole (“CDDO-2P-Im”) and 1-[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4(-pyridin-3-yl)-1H-imidazole (“CDDO-3P-Im”). | 2022-05-05 |
20220133749 | METHODS AND COMPOSITIONS FOR TREATING CANCER - Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17α-hydroxylase/C | 2022-05-05 |
20220133750 | MATRIX MESALAMINE EXTENDED RELEASE MINITABLETS AND ITS PROCESS THEREOF - Compositions for development of matrix type extended release mesalamine minitablets without use of any modified release coating, comprising a) mesalamine or its prodrug or derivatives thereof having a weight percentage in a range of 65-85 weight percentage with respect to the composition; b) at least one intragranular excipient having a weight percentage in a range of 3.5-22.5 weight percentage with respect to the composition; c) at least one binder having a weight percentage in a range of 2-6.5 weight percent with respect to the composition; and d) at least one extra granular excipient having a weight percentage in a range of 2-5 weight percentage with respect to the composition such that largest dimension in the minitablet is range of 1.00 mm to 2.8 mm. In another aspect of the present disclosure provides for a process of preparation of composition. | 2022-05-05 |
20220133751 | METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS - The present disclosure provides methods of treating a myeloproliferative disorder. In some aspects, the present disclosure provides methods of treating, stabilizing or lessening the severity or progression of one or more myeloproliferative disorders comprising administering to a patient previously treated with ruxolitinib a pharmaceutically acceptable composition comprising a compound of formula I, also known as fedratinib, or a pharmaceutically acceptable salt or hydrate thereof. | 2022-05-05 |
20220133752 | MINOCYCLINE FOR THE TREATMENT OF PITT-HOPKINS SYNDROME - The present invention relates to minocycline or a pharmaceutically acceptable sale thereof, for use in the treatment of Pitt-Hopkins syndrome. | 2022-05-05 |
20220133753 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES CHARACTERIZED BY INSUFFICIENT PANTOTHENATE KINASE ACTIVITY - Methods and pharmaceutical compositions for use in treating diseases associated with insufficient activity of the pantothenate kinase enzyme (e.g., CASTOR diseases) are disclosed. The methods and compositions involve an effective amount of an active derivative of 4′-phosphopantetheine. | 2022-05-05 |
20220133754 | METHOD FOR HYDRATING LYOPHILIZED CYCLOPHOSPHAMIDE COMPOSITION AND PRODUCT THEREOF - Provided are a hydration method for a lyophilized cyclophosphamide composition and a composition and preparation prepared thereby. The hydration method comprises: (a) providing an aqueous solution comprising cyclophosphamide and an optional pharmaceutically acceptable excipient; (b) freeze-drying the solution to obtain a lyophilized composition; and (c) hydrating the lyophilized composition by using liquid water to obtain the product. | 2022-05-05 |
20220133755 | COMPOSITION COMPRISING KETONE BODY AND NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATOR AND METHYL DONOR - The present invention provides a composition comprising a mixture of an exogenous ketone body, an exogenous NAD modulator and a methyl donor. Typically, exogenous NAD modulator is an exogenous nicotinamide adenine dinucleotide (NAD) precursor. The present invention also provides a method of using such a composition for treating various clinical conditions, including metabolic disorders and neurocognitive impairments. The compositions of the invention can also be used to improve human performance in various competitive or environmental conditions. | 2022-05-05 |
20220133756 | FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST FILOVIRUSES AND FLAVIVIRUSES - The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting flaviviruses, filoviruses and/or coronaviruses. | 2022-05-05 |
20220133757 | AQUEOUS COMPOSITIONS OF BORTEZOMIB - Provided herein are novel ready-to-use bortezomib formulations, methods of preparing, and methods of using the same. | 2022-05-05 |
20220133758 | TREATMENT OF INFLAMMATORY BOWEL DISEASES WITH 2'-FUCOSYLLACTOSE COMPOUNDS - Provided herein are 2′-fucosyllactose compounds and methods of using such for treating inflammatory bowel diseases (IBD) (e.g., Crohn's disease (CD) or ulcerative colitis (UC)) or alleviating or reducing the risk of relapse in IBD. | 2022-05-05 |
20220133759 | SYNTHETIC COMPOSITION - A method of increasing the relative abundance of | 2022-05-05 |
20220133760 | IDENTIFICATION AND TREATMENT OF T-CELL EPITOPES OF SHORT H2A ONCOHISTONES - The present disclosure describes methods of treating lymphoma that expresses a short histone H2A variant. In some embodiments, the method can comprise collecting a sample from a subject having or suspected of having lymphoma, detecting a short histone H2A variant (sH2A) expression level in the sample collected from the subject, and administering to the subject a therapeutically effective dose of an anthracycline agent, if the subject has sH2A variant expression level that is detectable. In other embodiments, the sH2A is the H2A.B variant. In other embodiments, the anthracycline agent can be aclarubicin. | 2022-05-05 |
20220133761 | NEUTROPHIL APOPTOSIS INDUCED BY NANOPARTICLES FOR TREATING INFLAMMATORY DISEASES - Disclosed are methods and compounds to selectively target the apoptosis pathway in proinflammatory neutrophils using Topoisomerase nanoparticles (NPs). The design of the disclosed nanoparticles (NPs) allows controlled release of DOX inside neutrophils, thus avoiding systemic toxicity. One such beneficial method for treating a subject neutrophil-inflammatory infection or tissue injury response includes administering a topoisomerase-conjugated albumin protein nanoparticles (NPs) composition to the subject, wherein the composition includes an effective amount so as to induce apoptosis of neutrophils, wherein the neutrophil induced inflammatory response is lower following the administration of the composition. | 2022-05-05 |
20220133762 | Method of Treating Cancer with Composition of Traditional Chinese Medicine and its Preparation Method Thereof - A method of treating cancer by natural traditional Chinese medicine with sustained release and its preparation method thereof, includes the steps of: administrating a composition of traditional Chinese medicine, wherein the composition contains active ingredients of: ginsenoside, Astragalus polysaccharide, zedoary ( | 2022-05-05 |
20220133763 | COMPOSITION CONTAINING NICOTINAMIDE MONONUCLEOTIDE AND MOGROSIDE, AND APPLICATION THEREOF - The present invention belongs to the medical and technical field and provides a medicine or health food composition of nicotinamide mononucleotide and mogroside. In addition, the present invention also provides the preparation method, formulation and application of the composition. | 2022-05-05 |
20220133764 | FLAVONOIDS AND ANIMAL HEALTH AND PERFORMANCE - The present invention relates to the use of naringin, its aglycone form naringenin or mixtures thereof in the modulation of the expression of some specific gene receptors in ruminants and/or pigs which positively impact on feeding behaviour, intake patterns and animal behaviour. | 2022-05-05 |
20220133765 | AMP-ACTIVATED PROTEIN KINASE ACTIVATING COMPOUNDS AND USES THEREOF - The present invention relates to pharmaceutical compounds, compositions and methods, especially as they relate to the treatment and/or prevention of conditions such as muscle disorders such as polymyositis, dermatomyositis, muscular dystrophy, myasthenia gravis, amyotrophic lateral sclerosis, rhabdomyolysis, and cardiomyopathy, brain disorders including Alzheimer's, stroke, cerebral atrophy, traumatic brain injury, and dementia, aging, diabetes, and cancer, using compounds of Formula (I): | 2022-05-05 |
20220133766 | MODULATION OF CILIOGENESIS - The disclosure is based on the finding that compounds capable of binding to (or interacting with) chromatin binding/remodelling complexes (for example Polycomb group PRC1 and Trithorax group MLL) and/or modulation of the same can be used to modulate (for example switch on/off) ciliogenesis as may occur, for example, in the human pulmonary bronchial epithelium. Provided are compounds, compositions, methods and medicaments which may be used to treat and/or prevent diseases and/or conditions associated with aberrant or defective ciliogenesis. | 2022-05-05 |
20220133767 | TARGETING MICRORNAS TO OVERCOME DRUG TOLERANCE AND RESISTANCE - The invention provides methods and compositions for use in targeting micro RNAs (miRNAs), as well as methods and compositions for use in treating, reducing, inhibiting, or delaying resistance or tolerance to anti-cancer treatment, and methods and compositions for use in treating or preventing cancer. | 2022-05-05 |
20220133768 | CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP) - CRISPR/RNA-guided nuclease-related compositions and methods for treatment of RHO-associated retinitis pigmentosa, e.g., autosomal-dominant retinitis pigmentosa (adRP). | 2022-05-05 |
20220133769 | Methods for Treatment of Alport Syndrome - Provided herein are methods for the treatment of Alport syndrome, using a modified oligonucleotide targeted to miR-21. In certain embodiments, the modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport syndrome. In certain embodiments, administration of the modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport syndrome. In certain embodiments, the modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport syndrome. | 2022-05-05 |
20220133770 | METHODS FOR TREATING MACROPHAGE-MEDIATED DISEASES, AND METHODS OF IDENTIFYING AGENTS USEFUL THEREFORE - Provided herein are methods of treating macrophage-mediated inflammatory diseases and disorders. Also, disclosed are methods for screening for agents useful in such methods. | 2022-05-05 |
20220133771 | Compositions and Methods for Treating or Preventing Gut Permeability-Related Disorders - Compositions and methods are provided for treating a gut permeability-related disease or disorder comprising administering to the gastrointestinal tract of a subject in need thereof, a therapeutically effective amount of a hydrogel having an elastic modulus (G′) of at least about 500 Pa. | 2022-05-05 |
20220133772 | MEDICATION - A medication is disclosed, and the medication includes carboxymethylated starch. The medication includes a citrate and/or citric acid for reducing postoperative adhesions. The citrate and/or citric acid is/are situated on the surface of granules of the starch, and includes 1 to 20 percent by weight of citrate and/or citric acid relative to the starch. A method of treating postoperative adhesions by administering the topical medication for reducing postoperative adhesions to a postoperative adhesion of a subject, and a use of the topical medication. | 2022-05-05 |
20220133773 | MEDICAMENT CONTAINING MODIFIED STARCH FOR THE TREATMENT OF ANASTOMOSES - According to the invention, a medicament a) containing or consisting of carboxymethylated starch and/or b) containing or consisting of epichlorohydrin-modified starch for treating anastomoses is disclosed. A method for preparing the medicament, and a use of the medicament. | 2022-05-05 |
20220133774 | MODULATION OF MICRORNAS AGAINST MYOTONIC DYSTROPHY TYPE 1 AND ANTAGONISTS OF MICRORNAS THEREFOR - Modulation of microRNAs against myotonic dystrophy type 1 and antagonists of microRNAs therefor. The invention provides the use of inhibitors of microRNAs repressors of MBNL1 and/or MBNL2 genes for the manufacture of a medicinal product for the treatment of myotonic dystrophy 1. Inhibiting these microRNAs allows to increase the endogenous levels of the corresponding proteins MBNL1 and/or MBNL2, thereby alleviating symptoms of the disease, especially when inhibiting repressors that are expressed in the main affected organs: skeletal muscle, heart or organs of the central nervous system. The inhibition of the microRNAs miR-23b-3p and miR-218-5p is preferred. It also provides oligoribonucleotide or oligoribonucleotide analogue antagonists suitable therefor, preferably antagomiRs directed against the microRNAs mentioned with chemical modifications that enhance their interaction with the target, their stability in vivo and their ability to penetrate into the cells and distribute throughout tissues and organs. | 2022-05-05 |
20220133775 | P-ETHOXY NUCLEIC ACIDS FOR IGF-1R INHIBITION - Provided herein are methods of treating cancer or an autoimmune disease comprising administering a liposome that comprises neutral phospholipids and a P-ethoxy oligonucleotide that targets a IGF-1R-encoding polynucleotide. | 2022-05-05 |
20220133776 | COMPOSITION INCLUDING GLUCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR - Provided are a composition comprising a GAG derivative and a chemokine receptor activity regulator, and a pharmaceutical composition comprising said composition. | 2022-05-05 |
20220133777 | METHODS OF TREATING UPPER GASTROINTESTINAL DISORDERS IN PPI REFRACTORY GERD - Disclosed herein are oral dosage forms of colesevelam, or a pharmaceutically acceptable salt thereof, adapted to treat upper gastro-intestinal disorders associated with PPI refractory GERD. Also disclosed are the methods of using these oral dosage forms to treat upper gastrointestinal disorders associated with PPI refractory, or PPI resistant, GERD in a patient in need thereof. The oral dosage forms disclosed herein are adapted for the ascribed uses by being comprised of colesevelam, or a pharmaceutically acceptable salt thereof, in a polymeric matrix comprised of one or more hydrophilic polymers such that the oral dosage form erodes upon encountering gastric fluid and has a gastric retention time of three hours or longer, allowing for an extended period of time for the colesevelam to be released in the upper GI and sequester excess bile. | 2022-05-05 |
20220133778 | PHARMACEUTICAL FORMULATIONS USEFUL FOR INHIBITING ACID SECRETION AND METHODS FOR MAKING AND USING THEM - The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to, a gastrointestinal disorder or disease in a subject in need thereof. | 2022-05-05 |
20220133779 | HYPOCHLOROUS ACID INTRAVENOUS SOLUTION, PREPARATION, AND METHOD OF USE THEREOF - Disclosed are intravenous solution compositions comprising hypochlorous acid (HOCl) suitable for systemic treatment or prevention of a variety of infections. | 2022-05-05 |
20220133780 | COMPOSITIONS AND METHODS FOR INTRACELLULAR IRON DISPLACEMENT PROTEINS - Methods and pharmaceutical compositions for optimizing intracellular iron by displacing iron bound transferrin (Tf) protein on a mammalian cell surface prior to its binding to a transferrin receptor (TfR), in the delivery of chromium chloride as being a Tf-binding agent to displace iron bound, and in the treatment of conditions involving disturbances in iron metabolism. | 2022-05-05 |
20220133781 | INTERNAL TEAT SEALANTS AND THEIR USE IN THE PREVENTION OF BOVINE MASTITIS IN THE DRY COWB - An intramammary syringe contains a seal formulation for forming a physical barrier in the teat canal of a non-human animal. The syringe contains a reduced volume of from 0.25 ml to 2.0 ml of the seal formulation. The problem of ascending sealant during the dry period is solved. | 2022-05-05 |
20220133782 | METHODS AND COMPOSITIONS FOR USING CINNAMALDEHYDE AND ZINC FOR WEIGHT MANAGEMENT - The invention pertains to a composition containing a combination of cinnamaldehyde and zinc. The composition containing the combination of cinnamaldehyde and zinc can be used in a method to support weight management or promote weight loss, a method for preventing obesity or overweight, and a method for treating obesity or overweight. In an embodiment, the composition containing the combination of cinnamaldehyde and zinc is administered to a human. The composition may be a medicament, a food product or a supplement. | 2022-05-05 |
20220133783 | ANTIVIRAL COMPOSITION AND USE OF THE SAME - Provided are an antiviral composition containing a cationic antiviral agent (cationic agent) and a copper salt to prevent, control or treat viral infections in a mammal, particularly in the nasopharyngeal and throat areas of humans and animals, and a method of preventing, controlling or treating viral infections in a mammal using the same. | 2022-05-05 |
20220133784 | MEDICINE FOR COVID-19 AND TREATMENT - The invention concerns a medicine and a prophylactic medicine for COVID-19 disease. The inventive medicine targets the endosomic, non-endosomic and/or intracellular viral pathways and inhibits them. The best mode of the invention is considered to be the medicine that blocks all three viral pathways. In the best mode the individual dose of a constituent component of the medicine is arranged to a dosage size sufficient to inhibit its designated SARS-CoV-2 viral pathway. This allows the dose of a particular pharmacological agent to be smaller than in a drug with just one kind of pharmacological agent. The best mode of the invention shuts the two cell membrane viral pathways and the one intracellular viral pathway with the minimum efficient dose, thereby preventing drug overdose, and enabling prophylactic or preventive use. | 2022-05-05 |
20220133785 | THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES - Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19. | 2022-05-05 |
20220133786 | THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES - Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19. | 2022-05-05 |
20220133787 | CELL COMPOSITION, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ATOPIC DISEASE COMPRISING SAME - A method for producing a cell composition according to an embodiment of the present disclosure includes separating and obtaining mononuclear cells and autologous plasma from human peripheral blood, coating a cell culture vessel with anti-CD3 antibody, and seeding the monocytes into the cell culture vessel and culturing the same in a medium containing at least one selected from the group consisting of IL-2, IL-12 and IL-18. The cell composition may have a proportion of interferon-gamma expressing cells that has increased to 60% or more among total cells, and as the proportion of cells continuously producing interferon-gamma is increased, atopic dermatitis can be significantly improved. In addition, it is expected that it will be possible to fundamentally treat immunological abnormalities of atopic dermatitis because the composition has no side effects and can be safely used for a long period of time. | 2022-05-05 |
20220133788 | BAFF THERAPY TO PROMOTE ANTI-TUMOR IMMUNITY - Anti-tumor immune response are generated by induction of activated B cells to provide costimulatory signals necessary for T cell activation. Certain compositions are combined with anti-immune checkpoint inhibitors to generate a synergistic anti-tumor response. | 2022-05-05 |
20220133789 | GENERATING CIK NKT CELLS FROM CORD BLOOD - Provided herein are methods and customized media compositions for culturing CIK NKT cells. | 2022-05-05 |
20220133790 | MODIFIED IMMUNE CELLS HAVING ENHANCED ANTI-NEOPLASIA ACTIVITY AND IMMUNOSUPPRESSION RESISTANCE - As described below, the present invention features genetically modified immune cells having enhanced anti-neoplasia activity, resistance to immune suppression, and decreased risk of eliciting a graft versus host reaction, or a combination thereof. The present invention also features methods for producing and using these modified immune effector cells. | 2022-05-05 |
20220133791 | A Combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject - The present invention provides a combination of compositions comprising i) a composition comprising I) a population of T cells, NK cells or cytotoxic immune effector cells comprising a chimeric antigen receptor specific for a stem cell antigen and/or, II) α) a population of T cells, NK cells or cytotoxic immune effector cells comprising a chimeric antigen receptor specific for a tag of a tagged polypeptide, wherein said tagged polypeptide binds specifically to a stem cell antigen, and β) said tagged polypeptide, and ii) a composition comprising a) a population of CD34+ hematopoietic stem cells, and b) one or more accessory or contributory cell populations selected from the group consisting of myeloid cell lineages expressing CD14, CD11b, CD11c, CD123, CD33; CD36; CD47, CD66b, CD235a, CD146 and CD326. A method applying these compositions to a subject in need thereof are also provided. | 2022-05-05 |
20220133792 | SIGNALING PLATFORMS FOR CHIMERIC ANTIGEN RECEPTOR T CELLS - Chimeric antigen receptors (CARs) are disclosed, along with nucleic acids and vectors encoding, and recombinant cells comprising such CARs and therapeutic compositions containing any of the foregoing. The CARs may comprise mutations that alter CAR expression, cytotoxicity, or cytokine production. Also provided are methods for using recombinant cells comprising these CARs for immunotherapy, e.g., in treating cancer by the administration of a therapeutically effective amount of one or more of the CAR polypeptides, nucleic acids, vectors, and/or immune cells, e.g., human CAR T cells, described herein optionally in combination with other immune and cancer treatments. | 2022-05-05 |
20220133793 | COMPOSITIONS AND METHODS FOR ENHANCED LYMPHOCYTE-MEDIATED IMMUNOTHERAPY - Lymphocytes having a suppressed autophagy gene useful in immunotherapy are disclosed. The lymphocytes can express an antigen targeting receptor such as a chimeric antigen receptor (CAR) or endogenous or engineered T-cell receptor to target cells expressing a tumor-specific antigen. Methods of making and using such lymphocytes are disclosed. Some such lymphocytes are useful in conducting CAR-T or TCR-T therapy. | 2022-05-05 |
20220133794 | THERAPEUTIC ANTIGEN BINDING PROTEINS SPECIFIC FOR CD93 AND METHODS OF USE THEREOF - Antigen binding domain polypeptides (ABD) specific for human CD93 are provided, which ABD may be formatted as antibodies, as chimeric antigen receptors, and the like. T cells comprising an anti-CD93 CAR are useful in the treatment of cancer, e.g. hematologic malignancies. | 2022-05-05 |
20220133795 | Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof - Methods of expanding peripheral blood lymphocytes (PBLs) from blood of patients with hematological malignancies, including lymphomas and leukemias, genetic modifications of expanded PBLs to incorporate chimeric antigen receptors, genetically modified T cell receptors, and other genetic modifications, and uses of such expanded and/or modified PBLs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein. | 2022-05-05 |
20220133796 | FUSION PROTEIN FOR USE IN THE TREATMENT OF HVG DISEASE - A fusion protein for use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 or SLA-01*0401 in a recipient patient who is negative for HLA-A*02 or SLA-01*0401, i.e. the patient prior to transplantation does not express HLA-A*02 or SLA-01*0401. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (T | 2022-05-05 |
20220133797 | NOTCH RECEPTORS WITH HINGE DOMAIN - The present disclosure generally relates to, inter alia, a new class of receptors engineered to modulate transcriptional regulation in a ligand-dependent manner. Particularly, the new receptors, even though derived from Notch, do not require the Notch negative regulatory regions previously believed to be essential for the functioning of the receptors. In addition, the new receptors described herein incorporate an extracellular oligomerization domain to promote oligomer formation of the chimeric receptors. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various health conditions such as cancers. | 2022-05-05 |
20220133798 | RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES - The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation. | 2022-05-05 |
20220133799 | COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT - Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. In certain instances, compositions may include additional agents. | 2022-05-05 |
20220133800 | TREATMENT OF DISEASE BASED ON IMMUNE CELL SEQUENCING - The present invention relates to treatment of disease, including treatment of antibody-mediated autoimmune disorders, as well as treatment of other conditions in which antibody therapeutics can be beneficial for targeting destruction of foreign or malignant cells. | 2022-05-05 |
20220133801 | ADMINISTRATION OF TUMOR INFILTRATING LYMPHOCYTES WITH MEMBRANE BOUND INTERLEUKIN 15 TO TREAT CANCER - Provided herein are tumor-infiltrating lymphocytes (TILs) engineered to express a membrane-bound interleukin 15 (mbIL15). The mbIL15 TILs can be expanded in vitro using a rapid expansion protocol without the use of exogenous interleukin 2 (IL2) and can be used in adoptive cell therapy without concomitant use of an exogenous cytokine such as IL2. The TIL can be further engineered such that the mbIL15 is operably linked to one or more drug responsive domains (DRDs), polypeptides that can regulate the abundance and/or activity of the IL15 upon binding of the DRD with a ligand. Also provided herein are components for making the modified TILs and methods for making and using the modified TILs. | 2022-05-05 |
20220133802 | FUSION POLYPEPTIDE FOR IMMUNOTHERAPY - The presently disclosed subject matter provides methods and compositions for enhancing immune responses toward tumor and pathogen antigens. It relates to fusion polypeptide that can be expressed in cells (e.g., immunoresponsive cells comprising an antigen-recognizing receptor) to improve the activity and/or efficiency of the cells. In certain embodiments, the fusion polypeptide comprises an extracellular domain and a transmembrane domain of a co-stimulatory ligand, and an intracellular domain of a co-stimulatory molecule. | 2022-05-05 |
20220133803 | METHOD AND SYSTEM FOR ISOLATION OF MESENCHYMAL STEM CELL EXOSOMES - Disclosed is a system and method for isolating large quantities of viable, undamaged exosomes from liquid, cell-free mesenchymal stem cell cultures using tangential flow filtration. | 2022-05-05 |
20220133804 | USE OF MESENCHYMAL STEM CELLS IN TREATING IMMUNE-RELATED DISEASES - Disclosed herein is a method of identifying a plurality of mesenchymal stem cells (MSCs) that are therapeutic to a subject having an immune-related disease, for example, arthritis. According to embodiments of the present disclosure, the MSCs exhibiting to the immune-related disease are characterized in having an immunosuppressive protein binding value (IPBv) greater than 170 toward indoleamine 2,3-dioxygenase (IDO) after being exposed to 50-800 U/ml of IFN-γ. Also disclosed herein are uses of the identified MSCs for the manufacture of a medicament, and methods of treating an immune-related disease by use of the identified MSCs or medicament. | 2022-05-05 |
20220133805 | PHARMACEUTICAL COMPOSITION FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to a pharmaceutical composition for treating amyotrophic lateral sclerosis. More specifically, the present invention relates to a pharmaceutical composition for treating amyotrophic lateral sclerosis, wherein the pharmaceutical composition comprises mesenchymal stem cells and is intravenously administered. | 2022-05-05 |
20220133806 | AMNIOTIC FLUID-DERIVED EXTRACELLULAR VESICLES AND USES THEREOF FOR WOUND HEALING - The described invention provides compositions and methods for wound healing in a subject. The methods include administering a therapeutic amount of a pharmaceutical composition comprising extracellular vesicles from amniotic fluid and a pharmaceutically acceptable carrier. | 2022-05-05 |
20220133807 | COMPOSITIONS DERIVED FROM HUMAN AMNION CELLS & RELATED METHODS - Methods of treating alopecia, connective tissue disease, or chronic skin wounds in a subject by administration of a therapeutically effective amount of a novel acellular human amnion-derived composition are disclosed. The novel acellular human amnion-derived composition is generally characterized as containing: one or more tissue-remodeling biomolecules, one or more proliferation biomolecules, one or more angiogenic biomolecules, one or more migration biomolecules, one or more anti-inflammatory biomolecules, and one or more anti-microbial biomolecules. Moreover, the acellular human amnion-derived composition is sterilized under conditions that preserve biological functionality and efficacy. Other features and characteristics of the treatment methods and compositions are described. | 2022-05-05 |
20220133808 | COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS - Described herein are compositions and methods for treating a patient having or at risk of developing a neurocognitive disorder, such as Alzheimer's disease, Parkinson's disease, and/or a frontotemporal lobar dementia. Using the compositions and methods of the disclosure, a patient, such as an adult human patient, may be provided one or more agents that elevate the expression and/or activity levels of a protein or series of proteins whose deficiency is associated with the corresponding disease. Exemplary agents that may be used in conjunction with the compositions and methods of the disclosure for this purpose include cells, such as cells, that contain nucleic acids encoding the protein or proteins of interest, as well as vectors, such as viral vectors, encoding the protein or proteins of interest. Additional examples of such agents include the protein or proteins themselves, as well as interfering RNA molecules that stimulate their endogenous expression. | 2022-05-05 |
20220133809 | METHOD TO PREPARE A THERAPEUTIC BALM - A method to prepare a therapeutic balm is disclosed. A first phase solution is prepared in an oak barrel using a grain neutral spirit. The first phase is mixed for 10 minutes per day for a month to prepare a second phase solution. The second phase solution is filtered at least twice to prepare a filtrate. The filtrate and third phase components are mixed to prepare a third phase solution. The third phase solution is mixed with a distilled wine liquor to prepare a fourth phase solution. The fourth phase solution is mixed at least twice a day for a month to prepare a fifth phase solution. The fifth phase solution is mixed with cranberry juice, pomegranate juice, and raspberry juice to prepare a sixth phase solution. The sixth phase solution is stored in a ceramic bottle for a least six months at room temperature to prepare a therapeutic balm. | 2022-05-05 |
20220133810 | LIQUID PROPOLIS EXTRACT, ITS FORMULATION AND USE THEREOF - A novel standardized liquid propolis extract and pharmaceutical formulation based on said extract, as well as their manufacturing methods and uses, are provided. The liquid extract is produced by extraction of crude propolis with an extraction solvent based on a mixture of PEG 200-600 (96.5-99.9% w/w) and lecithins (0.1-3.5% w/w). The extract is characterized with standardized content of p-coumaric acid (1), trans-ferulic acid (2), caffeic acid (3), and CAPE (4). It is used as an active ingredient in manufacturing of pharmaceutical, cosmetic, veterinary, agrochemical or functional food products. The pharmaceutical formulation according to the invention consists of 5-95% w/w of the said propolis extract and up to 100% excipients required for preparation of various dosage forms. It is used for treatment of diseases and conditions in humans and animals such as: inflammatory diseases, bacterial and fungal infections, viral, autoimmune and cancer diseases, and for the treatment of burns and wound healing. | 2022-05-05 |
20220133811 | AKKERMANSIA MUCINIPHILA EB-AMDK27 STRAIN AND USE THEREOF - Disclosed are a novel | 2022-05-05 |
20220133812 | AKKERMANSIA MUCINIPHILA EB-AMDK19 STRAIN AND USE THEREOF - Disclosed are a novel | 2022-05-05 |
20220133813 | COMPOSITIONS AND METHODS FOR THE INDUCTION OF CD8+ T-CELLS - Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells. | 2022-05-05 |
20220133814 | FAECALIBACTERIUM PRAUSNITZII AND DESULFOVIBRIO PIGER FOR USE IN THE TREATMENT OR PREVENTION OF DIABETES AND BOWEL DISEASES - The present invention relates generally to medicine. More specifically the invention relates to the use of synergistic probiotic bacteria as intervention for health. | 2022-05-05 |
20220133815 | MUSCLE-MODIFYING AGENT - A method for causing a qualitative change in muscle fibers of a human or animal individual, includes the oral administration of a feed incorporating fermentation product dissolving solutions of thermophilic bacteria or | 2022-05-05 |
20220133816 | FEED ADDITIVE FORMULATION AND METHODS OF MAKING AND USING THE SAME - The presently disclosed subject matter relates to feed additive formulations for monogastric animal feed. Particularly, the disclosed formulations comprise an isolated xylanase enzyme and a | 2022-05-05 |
20220133817 | Recombinant Bacteria And Uses Thereof - The present disclosure provides a recombinant, probiotic lactic acid bacterium, wherein the bacterium comprises a non-replicating plasmid vector comprising (a) a tumor suppressor gene or anti-inflammatory gene operably linked to a first promoter that directs expression of the tumor suppressor gene or anti-inflammatory gene in a mammalian cell, and (b) an adhesin gene operably linked to a second promoter that directs expression of the adhesin gene in the bacterium. The present disclosure also provides uses of the recombinant bacterium, and methods of constructing the recombinant bacterium. The present disclosure also provides a method of treating cancer in a subject, wherein the method comprises administering a pharmaceutically effective amount of a recombinant, probiotic lactic acid bacterium, wherein the bacterium comprises a non-replicating plasmid vector comprising an adhesin gene operably linked to a promoter that directs expression of the adhesin gene in the bacterium. | 2022-05-05 |
20220133818 | METHOD AND COMPOSITION FOR TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS - Methods of treating, reducing the risk of, preventing, or alleviating a symptom of inflammation or inflammatory gastrointestinal disease by administration of a modified bacterium providing purines, in particular hypoxanthine, to the mucosa of the intestine, and compositions containing modified bacteria useful in such methods. | 2022-05-05 |
20220133819 | MULTI-LACTOBACILLUS COMPOSITION AND APPLICATION THEREOF TO VAGINAL HEALTH OF FEMALES - A multi-lactobacillus composition is a dominant strain separated and selected from the vagina of a healthy woman in China. The multi-lactobacillus composition comprises at least three of the following active components: | 2022-05-05 |
20220133820 | Application of breast milk-derived Lactobacillus reuteri in regulating maternal and infant immune function - The disclosure discloses application of breast milk-derived | 2022-05-05 |